| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/DMRR.794 |
| P698 | PubMed publication ID | 17966969 |
| P2093 | author name string | Agostino Consoli | |
| Assunta Pandolfi | |||
| Antonio Nicolucci | |||
| Elena A De Filippis | |||
| Giovanni Davì | |||
| Tonino Bucciarelli | |||
| Gloria Formoso | |||
| Giovanni Ciabattoni | |||
| Noemi Michetti | |||
| Patrizia Di Fulvio | |||
| P2860 | cites work | Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice | Q24805374 |
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
| Platelet activation in type 2 diabetes mellitus | Q28210554 | ||
| Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group | Q29547282 | ||
| Clinical relevance of the oxidative stress concept. | Q33849775 | ||
| Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo | Q33864159 | ||
| Lipid peroxidation in diabetes mellitus | Q34384380 | ||
| Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes | Q34953482 | ||
| Diabetes, oxidative stress, and antioxidants: a review | Q35077717 | ||
| Glomerular actions of a free radical-generated novel prostaglandin, 8-epi-prostaglandin F2 alpha, in the rat. Evidence for interaction with thromboxane A2 receptors | Q35603673 | ||
| Isoprostane formation and inhibition in atherothrombosis | Q36076212 | ||
| Oxidant stress, inflammation and atherogenesis | Q36283507 | ||
| Antidiabetic and antimalarial biguanide drugs are metal-interactive antiproteolytic agents | Q40569580 | ||
| Antiplatelet agents in the prevention of diabetic vascular complications. | Q40754772 | ||
| In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. | Q42536696 | ||
| Monotherapy with metformin: does it improve hypoxia in type 2 diabetic patients? | Q43767224 | ||
| An intracellular modulation of free radical production could contribute to the beneficial effects of metformin towards oxidative stress | Q44449233 | ||
| Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. | Q44518897 | ||
| Diabetes mellitus, oxidative stress and advanced glycation endproducts | Q44970615 | ||
| Thromboxane biosynthesis and platelet function in type II diabetes mellitus | Q45056796 | ||
| Metformin prevents glucose-induced protein kinase C-beta2 activation in human umbilical vein endothelial cells through an antioxidant mechanism | Q46406560 | ||
| Assessing the predictive accuracy of QUICKI as a surrogate index for insulin sensitivity using a calibration model | Q46570511 | ||
| In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia. | Q50917467 | ||
| Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. | Q50944772 | ||
| Effect of metformin on glutathione and magnesium in normal and streptozotocin-induced diabetic rats. | Q51585764 | ||
| An insulin sensitizer improves the free radical defense system potential and insulin sensitivity in high fructose-fed rats. | Q54095655 | ||
| Radioimmunoassay of 11-dehydrothromboxane B2 in human plasma and urine. | Q54137065 | ||
| Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. | Q54243732 | ||
| Metformin reduces platelet hypersensitivity in hypercholesterolemic rabbits | Q57399014 | ||
| The F2-isoprostane, 8-epi-prostaglandin F2 alpha, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/endoperoxide receptor antagonist | Q67584372 | ||
| Study of the effect of metformin on platelet aggregation in insulin-dependent diabetics | Q69579971 | ||
| Increased production of platelet thromboxane B2 in non-insulin-dependent diabetes. Relationship to vascular complications | Q70484534 | ||
| Platelets from patients with diabetes mellitus have impaired ability to mediate vasodilation | Q71071086 | ||
| The mystery of diabetes and atherosclerosis: time for a new plot | Q73070861 | ||
| Effect of four-week metformin treatment on plasma and erythrocyte antioxidative defense enzymes in newly diagnosed obese patients with type 2 diabetes | Q73557293 | ||
| Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes | Q78044125 | ||
| Metformin reduces endothelial cell expression of both the receptor for advanced glycation end products and lectin-like oxidized receptor 1 | Q79756457 | ||
| P433 | issue | 3 | |
| P921 | main subject | metformin | Q19484 |
| P304 | page(s) | 231-237 | |
| P577 | publication date | 2008-03-01 | |
| P1433 | published in | Diabetes - Metabolism: Research and Reviews | Q15750056 |
| P1476 | title | Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects | |
| P478 | volume | 24 |
| Q38780360 | Antioxidant properties of drugs used in Type 2 diabetes management: could they contribute to, confound or conceal effects of antioxidant therapy? |
| Q39200522 | Antiplatelet activity of drugs used in hypertension, dyslipidemia and diabetes: Additional benefit in cardiovascular diseases prevention. |
| Q35592932 | Comparison of glucose lowering effect of metformin and acarbose in type 2 diabetes mellitus: a meta-analysis |
| Q42849047 | Effects of metformin plus gliclazide compared with metformin alone on circulating endothelial progenitor cell in type 2 diabetic patients |
| Q54359594 | Energy and motion: AMP-activated protein kinase α1 and its role in platelet activation. |
| Q37195539 | HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options |
| Q33750626 | Increased glycation and oxidative damage to apolipoprotein B100 of LDL cholesterol in patients with type 2 diabetes and effect of metformin |
| Q35044151 | Long-term insulin glargine therapy in type 2 diabetes mellitus: a focus on cardiovascular outcomes. |
| Q37619208 | Metformin Impairs Spatial Memory and Visual Acuity in Old Male Mice |
| Q40867355 | Metformin prevents ischemia reperfusion-induced oxidative stress in the fatty liver by attenuation of reactive oxygen species formation. |
| Q51366721 | Metformin restores the correlation between serum-oxidized LDL and leptin levels in type 2 diabetic patients. |
| Q64074179 | Metformin use mitigates the adverse prognostic effect of diabetes mellitus in chronic obstructive pulmonary disease |
| Q38585518 | Oxidative stress in chronic vascular disease: From prediction to prevention. |
| Q92044310 | Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies |
| Q37932076 | Platelet activation in obesity and metabolic syndrome |
| Q37270256 | Platelet size and density affect shear-induced thrombus formation in tortuous arterioles |
| Q92441493 | Pleiotropic Activity of Metformin and Its Sulfonamide Derivatives on Vascular and Platelet Haemostasis |
| Q91704326 | Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs |
| Q36771663 | Prolonged metformin treatment leads to reduced transcription of Nrf2 and neurotrophic factors without cognitive impairment in older C57BL/6J mice |
| Q46230278 | Protective effect of metformin against retinal vein occlusions in diabetes mellitus - A nationwide population-based study. |
| Q24235718 | Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus |
| Q24240522 | Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus |
| Q51135053 | Safety of Metformin in Patients with Chronic Obstructive Pulmonary Disease and Type 2 Diabetes Mellitus. |
| Q41262030 | Safety of metformin in patients with chronic obstructive pulmonary disease and type 2 diabetes mellitus. |
| Q37798968 | The role of calpain in diabetes-associated platelet hyperactivation. |
| Q87157416 | Treatment of hyperglycaemia in newly diagnosed diabetic patients is associated with a reduction in oxidative stress and improvement in β-cell function |
Search more.